Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study

Inclusion Criteria: * Newly diagnosed type I diabetic patients * Type I diabetes treated with basal-bolus regimen including 3 or more injections of Regular Human Insulin per day * BMI, 26-40 kg/m2 * HbA1c, 7.5%-10% * Median 2Hrs post -prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/L) * FPG more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/L) * Willingness to accept, and ability to inject insulin Glargine therapy Exclusion Criteria: * Pregnancy : The use of LANTUS \& APIDRA during pregnancy is not contraindicated. However, in the absence of supportive data, Sanofi- Aventis Pharmaceuticals cannot specifically recommend the use of Lantus in this patient population The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial